Nisa Investment Advisors LLC Sells 5,944 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Nisa Investment Advisors LLC lowered its position in HCA Healthcare, Inc. (NYSE:HCA) by 8.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 67,033 shares of the company’s stock after selling 5,944 shares during the period. Nisa Investment Advisors LLC’s holdings in HCA Healthcare were worth $20,120,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HCA. MML Investors Services LLC boosted its position in shares of HCA Healthcare by 31.7% in the 3rd quarter. MML Investors Services LLC now owns 17,816 shares of the company’s stock worth $7,241,000 after purchasing an additional 4,285 shares in the last quarter. Meritage Group LP acquired a new position in shares of HCA Healthcare during the third quarter valued at about $150,548,000. Alpha DNA Investment Management LLC acquired a new stake in HCA Healthcare in the 3rd quarter worth approximately $869,000. NRI Wealth Management LC purchased a new position in shares of HCA Healthcare in the fourth quarter worth $2,896,000. Finally, Czech National Bank increased its position in shares of HCA Healthcare by 4.5% in the 4th quarter. Czech National Bank now owns 39,543 shares of the company’s stock valued at $11,869,000 after acquiring an additional 1,691 shares during the period. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Price Performance

HCA Healthcare stock opened at $319.53 on Thursday. The firm has a market capitalization of $80.94 billion, a price-to-earnings ratio of 14.35, a PEG ratio of 1.06 and a beta of 1.64. HCA Healthcare, Inc. has a 52-week low of $278.68 and a 52-week high of $417.14. The company has a fifty day simple moving average of $315.10 and a 200-day simple moving average of $353.07. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71.

HCA Healthcare Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, December 27th. Investors of record on Friday, December 13th were issued a $0.66 dividend. The ex-dividend date was Friday, December 13th. This represents a $2.64 annualized dividend and a dividend yield of 0.83%. HCA Healthcare’s dividend payout ratio is presently 11.85%.

Insiders Place Their Bets

In other news, SVP Phillip G. Billington sold 3,897 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the completion of the sale, the senior vice president now owns 52,702 shares of the company’s stock, valued at $18,445,700. This represents a 6.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Erol R. Akdamar sold 2,900 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the transaction, the insider now owns 6,843 shares of the company’s stock, valued at approximately $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. StockNews.com lowered HCA Healthcare from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Oppenheimer lifted their price objective on shares of HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a research note on Monday, October 28th. Morgan Stanley reduced their target price on shares of HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $380.00 price target on shares of HCA Healthcare in a research report on Tuesday, December 17th. Finally, Raymond James lowered HCA Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $385.27.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.